Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Protocol voor uniforme behandeling van alvleesklierkanker
mrt 2021 | Chirurgie, Maag-darm-leveroncologie